Zepto® has been demonstrated in a FDA clinical trial to be safe and effective.  No change in corneal incision size was observed after Zepto use in 70% of cases, and a mean enlargement of 30 micron was encountered in 30% of cases.  No differences in ocular condition have been observed after Zepto use compared to CCC, with a peak temperature increase of 1-2°C for a fraction of a second.

View Miyake-Apple Imaging of Zonular Tissue During Zepto Use

View Temperature Testing and Data Sheet

Download Peer Reviewed Publication of Zepto Capsulotomy Strength Testing

Download Peer Reviewed Publication with Zepto Product Performance Review


19 Feb Mynosys Cellular Devices Inc. Receives Import Authority From South Korea for Zepto® Mynosys Cellular Devices Inc. receives import authority from South ... read more ›
17 Feb Zepto® Approved for Sale in Canada We are pleased to announce that our Zepto Capsulotomy System has been ... read more ›
22 Sep Ophthalmology Futures Forum – ESCRS, Vienna Mynosys will be exhibiting its new Zepto Capsulotomy System at the ... read more ›